PALISADE BIO INC (PALI) — insider trading
Health Care · NASDAQ
PALISADE BIO INC (PALI) has 37 reported SEC Form 4 insider transactions in our data, including 8 open-market purchases and 2 open-market sales among the most recent 37 (latest 2026-10-06).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Jones Mitchell Lawrence | Officer (See Remarks) | Option exercise / conversion (derivative) | 65,584 | — | $0 | Form 4 |
| 2026-10-06 | Jones Mitchell Lawrence | Officer (See Remarks) | Option exercise / conversion (derivative) | 2,555,266 | — | $0 | Form 4 |
| 2026-10-06 | Jones Mitchell Lawrence | Officer (See Remarks) | Shares withheld for taxes / exercise cost | 1,031,102 | $1.49 | $1.54M | Form 4 |
| 2026-10-06 | Jones Mitchell Lawrence | Officer (See Remarks) | Option exercise / conversion | 2,620,850 | — | — | Form 4 |
| 2026-10-06 | Finley John David | Director, Officer (CEO CFO) | Option exercise / conversion (derivative) | 167,584 | — | $0 | Form 4 |
| 2026-10-06 | Finley John David | Director, Officer (CEO CFO) | Option exercise / conversion (derivative) | 3,059,800 | — | $0 | Form 4 |
| 2026-10-06 | Finley John David | Director, Officer (CEO CFO) | Shares withheld for taxes / exercise cost | 1,411,982 | $1.49 | $2.10M | Form 4 |
| 2026-10-06 | Finley John David | Director, Officer (CEO CFO) | Option exercise / conversion | 3,227,384 | — | — | Form 4 |
| 2026-10-02 | Williams Donald Allen | Director | Open-market purchase | 10,000 | $1.46 | $14.6K | Form 4 |
| 2026-10-01 | Williams Donald Allen | Director | Open-market purchase | 10,000 | $1.42 | $14.2K | Form 4 |
| 2026-08-19 | Finley John David | Director, Officer (CEO, CFO) | Bona fide gift | 88,400 | — | $0 | Form 4 |
| 2026-08-19 | Finley John David | Director, Officer (CEO, CFO) | Bona fide gift | 88,400 | — | $0 | Form 4 |
| 2026-07-09 | Baltera Robert Jr. | Director | Open-market purchase | 25,000 | $1.96 | $48.9K | Form 4 |
| 2026-07-08 | Baltera Robert Jr. | Director | Open-market purchase | 20,000 | $1.99 | $39.8K | Form 4 |
| 2026-07-07 | Finley John David | Director, Officer (CEO, CFO) | Option exercise / conversion (derivative) | 133 | — | $0 | Form 4 |
| 2026-07-07 | Finley John David | Director, Officer (CEO, CFO) | Option exercise / conversion | 133 | $0.7 | $93 | Form 4 |
| 2026-07-07 | Finley John David | Director, Officer (CEO, CFO) | Open-market sale | 146,798 | $2.07 | $303.3K | Form 4 |
| 2026-07-07 | Jones Mitchell Lawrence | Officer (Chief Medical Officer) | Open-market sale | 51,880 | $2.05 | $106.5K | Form 4 |
| 2026-07-07 | Baltera Robert Jr. | Director | Open-market purchase | 30,000 | $2.03 | $61.0K | Form 4 |
| 2026-07-06 | Finley John David | Director, Officer (CEO, CFO) | Option exercise / conversion (derivative) | 335,167 | — | $0 | Form 4 |
| 2026-07-06 | Finley John David | Director, Officer (CEO, CFO) | Option exercise / conversion | 335,167 | — | — | Form 4 |
| 2026-07-06 | Jones Mitchell Lawrence | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 131,167 | — | $0 | Form 4 |
| 2026-07-06 | Jones Mitchell Lawrence | Officer (Chief Medical Officer) | Option exercise / conversion | 131,167 | — | — | Form 4 |
| 2026-07-06 | Baltera Robert Jr. | Director | Open-market purchase | 20,000 | $2.05 | $41.0K | Form 4 |
| 2026-07-02 | Baltera Robert Jr. | Director | Open-market purchase | 10,000 | $1.98 | $19.8K | Form 4 |
| 2026-07-01 | Baltera Robert Jr. | Director | Open-market purchase | 20,000 | $1.98 | $39.6K | Form 4 |
| 2026-06-10 | Baltera Robert Jr. | Director | Grant / award / vesting | 336,904 | — | — | Form 4 |
| 2026-06-10 | Zwick Jordan Michael | Director | Grant / award / vesting | 336,904 | — | — | Form 4 |
| 2026-06-10 | Chuang Emil | Director | Option exercise / conversion (derivative) | 20,200 | — | $0 | Form 4 |
| 2026-06-10 | Chuang Emil | Director | Option exercise / conversion | 20,200 | — | — | Form 4 |
| 2026-06-10 | Chuang Emil | Director | Grant / award / vesting | 592,300 | — | — | Form 4 |
| 2026-06-10 | Williams Donald Allen | Director | Option exercise / conversion (derivative) | 60,666 | — | $0 | Form 4 |
| 2026-06-10 | Williams Donald Allen | Director | Option exercise / conversion | 60,666 | — | — | Form 4 |
| 2026-06-10 | Williams Donald Allen | Director | Grant / award / vesting | 1,498,900 | — | — | Form 4 |
| 2026-06-10 | Wei Binxian | Director | Option exercise / conversion (derivative) | 20,200 | — | $0 | Form 4 |
| 2026-06-10 | Wei Binxian | Director | Option exercise / conversion | 20,200 | — | — | Form 4 |
| 2026-06-10 | Wei Binxian | Director | Grant / award / vesting | 592,300 | — | — | Form 4 |
Ask the chat about PALI's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: PALISADE BIO INC (PALI).
Last updated 2026-10-06 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.